Infusystem Holdings, Inc key statistics and ratios

In fiscal 2025, Infusystem Holdings, Inc had return on equity of 11.5%, an operating margin of 8.3%, debt equal to 34.9% of equity and a current ratio of 1.80. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Infusystem Holdings, Inc: financial ratios, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Gross margin	73.5%	71.0%	64.7%	72.9%	70.1%	71.2%	70.3%	63.5%	61.0%	58.9%	57.8%	60.3%	57.2%	55.1%	50.2%	52.2%	56.0%	57.5%
Operating margin	13.7%	−2.0%	−121.4%	3.4%	9.5%	14.0%	10.3%	1.4%	−5.4%	0.6%	4.3%	9.1%	2.8%	1.5%	3.3%	5.1%	8.3%	9.3%
Net margin	2.0%	−3.9%	−83.2%	−2.5%	2.7%	5.0%	3.9%	−0.3%	−29.1%	−1.6%	1.7%	17.8%	1.4%	0.0%	0.7%	1.7%	4.6%	6.0%
Free-cash-flow margin	13.1%	17.7%	−2.7%	−1.9%	4.4%	7.9%	9.6%	11.0%	10.7%	16.5%	13.5%	19.7%	16.9%	15.0%	8.1%	14.4%	16.6%	16.0%
Return on equity	1.0%	−2.2%	−72.5%	−3.7%	4.0%	7.5%	5.8%	−0.4%	−50.7%	−4.3%	6.4%	54.9%	3.2%	0.0%	1.7%	4.3%	11.5%	14.7%
Return on assets	—	−1.4%	−44.0%	−1.9%	2.2%	4.3%	3.2%	−0.2%	−25.1%	−1.6%	1.9%	19.7%	1.5%	0.0%	0.9%	2.3%	6.5%	8.6%
Asset turnover	—	0.36	0.53	0.77	0.80	0.84	0.80	0.74	0.86	1.01	1.13	1.11	1.05	1.12	1.24	1.31	1.41	1.45
Current ratio	—	1.23	0.85	1.45	1.22	1.05	1.24	1.26	1.42	1.19	0.88	1.29	1.71	1.71	1.95	1.82	1.80	2.50
Debt to equity	0.0%	37.8%	72.5%	78.1%	62.6%	54.9%	69.4%	62.9%	91.7%	165.1%	171.8%	95.4%	69.2%	69.5%	56.3%	41.9%	34.9%	35.1%
Interest cover (operating income ÷ interest)	1.5x	n/m	n/m	0.6x	1.7x	3.0x	4.3x	0.7x	n/m	0.3x	1.9x	7.0x	2.0x	1.2x	1.9x	3.9x	9.2x	12.1x
Effective tax rate	55.8%	—	—	—	38.2%	45.9%	30.2%	—	—	—	10.7%	—	−13.0%	86.2%	52.9%	53.6%	37.6%	30.0%
Capital spending as % of revenue	11.8%	5.2%	15.0%	11.1%	7.6%	3.0%	0.4%	0.2%	0.1%	0.4%	3.6%	1.1%	1.0%	0.9%	0.8%	0.8%	0.4%	0.3%
Free cash flow ÷ net income	658.4%	—	—	—	164.2%	156.7%	242.0%	—	—	—	804.5%	110.7%	>999%	>999%	>999%	825.9%	359.9%	268.1%
Dividends and buybacks ÷ free cash flow	—	0.8%	—	—	2.9%	3.9%	2.7%	1.0%	—	93.6%	0.0%	0.0%	3.2%	33.0%	1.5%	6.1%	41.4%	34.2%

US$ thousands unless shown otherwise. Fiscal quarters.

Infusystem Holdings, Inc: financial ratios, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Gross margin	53.9%	53.8%	55.2%	55.2%	57.1%	56.4%	58.4%	58.0%
Operating margin	9.2%	7.7%	1.8%	10.5%	10.4%	10.3%	4.7%	11.2%
Net margin	5.1%	2.8%	−0.8%	7.2%	6.2%	5.6%	3.0%	8.7%
Free-cash-flow margin	27.7%	21.9%	4.8%	18.9%	23.1%	19.3%	2.4%	18.1%
Current ratio	1.98	1.82	2.21	2.19	1.90	1.80	2.14	2.50
Debt to equity	50.4%	41.5%	52.1%	48.3%	37.7%	34.2%	33.4%	34.5%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

6 of 7 checks passed · June 30, 2026

What it owns · $98m

Short-term assets $38mLonger-term assets $59m

What it owes, and who funded it · $98m

Short-term liabilities $15mLonger-term liabilities $23mShareholders' equity $59m

Short-term assets cover short-term liabilities $38m of assets due within a year against $15m of liabilities due within a year.
Short-term assets cover long-term liabilities $38m short-term assets against $23m of longer-dated liabilities.
More cash than debt $964,000 of cash against $20m of debt.
Debt below 40% of shareholders' equity Debt is 35% of equity.
Debt burden no higher than five years ago Debt to equity moved from 68% to 35% over five years.
A year's operating cash flow covers at least 20% of debt $23m of operating cash flow against $20m of debt.
Operating profit covers interest at least five times over Operating income of $13m against $1m of interest.

From Infusystem Holdings, Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

64 /100

Moderate moat

How hard Infusystem Holdings's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 11 / 20

Cash operating profit has been a median 9.2% of total assets over 10 years.
Pricing power 18 / 20

Gross margin has been a median 57.4%, moving by 3.6 percentage points (standard deviation) across 10 years.
Durability 0 / 20

Operating margin has been a median 2.8%; its worst year was -4.3%.
Cash conversion 18 / 20

Free cash flow was positive in 10 of 10 years, at a median 16.4% of revenue.
Discipline 17 / 20

The diluted share count fell 5.9% over five years; stock-based pay has been a median 3.2% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: INFU vs STIM INFU vs RXST BBNX vs INFU

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Infusystem Holdings, Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Infusystem Holdings, Inc.